Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel subanalysis of the csps.com trial

Haruhiko Hoshino, Kazunori Toyoda, Katsuhiro Omae, Noriyuki Ishida, Shinichiro Uchiyama, Kazumi Kimura, Nobuyuki Sakai, Yasushi Okada, Kortaro Tanaka, Hideki Origasa, Hiroaki Naritomi, Kiyohiro Houkin, Keiji Yamaguchi, Masanori Isobe, Kazuo Minematsu, Masayasu Matsumoto, Teiji Tominaga, Hidekazu Tomimoto, Yasuo Terayama, Satoshi YasudaTakenori Yamaguchi

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND AND PURPOSE: Although dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the recurrence of ischemic stroke while significantly increasing the bleeding events compared with monotherapy, the CSPS.com trial (Cilostazol Stroke Prevention Study combination) showed that DAPT using cilostazol was more effective without the bleeding risk. In the CSPS.com trial, aspirin or clopidogrel was used as the underlying antiplatelet drug. The effectiveness and safety of each combination were examined and clarified. METHODS: In the CSPS.com trial, a multicenter, open-label, randomized controlled study, patients with high-risk, noncardioembolic ischemic stroke 8 to 180 days after onset treated with aspirin or clopidogrel alone at the discretion of the physician in charge were recruited. Patients were randomly assigned to receive either monotherapy or DAPT using cilostazol and followed for 0.5 to 3.5 years. The primary efficacy outcome was first recurrence of ischemic stroke. The safety outcome was severe or life-threatening bleeding. The analysis was based on the underlying antiplatelet agents. RESULTS: A total of 763 patients taking aspirin and 1116 taking clopidogrel were included in the intention-to-treat analysis. Although the clopidogrel group had more risk factors than the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the 2 groups. In the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the DAPT group and the aspirin-monotherapy group. In the clopidogrel group, the primary end point occurred at a rate of 2.31 per 100 patient-years in the DAPT group and 5.19 per 100 patient-years in the clopidogrelmonotherapy group (hazard ratio, 0.447 [95% CI, 0.258-0.774]). Safety outcome did not differ significantly between groups (0.51 per 100 patient-years versus 0.71 per 100 patient-years, respectively; hazard ratio, 0.730 [95% CI, 0.206-2.588]). CONCLUSIONS: The combination of cilostazol and clopidogrel significantly reduced the recurrence of ischemic stroke without increasing the bleeding risk in noncardioembolic, high-risk patients.

Original languageEnglish
Pages (from-to)3430-3439
Number of pages10
JournalStroke
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • Cilostazol
  • Clopidogrel
  • Dual anti-platelet therapy
  • High-risk
  • Noncardioembolic ischemic stroke
  • Secondary prevention

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialised Nursing

Fingerprint

Dive into the research topics of 'Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel subanalysis of the csps.com trial'. Together they form a unique fingerprint.

Cite this